{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:52:25Z","timestamp":1776091945544,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182512","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T21:29:05Z","timestamp":1502486945000},"page":"e0182512","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1728-5092","authenticated-orcid":true,"given":"Christina","family":"Siesing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halfdan","family":"Sorbye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Qvortrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Pont\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"issue":"2","key":"ref1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"LA Torre","year":"2015","journal-title":"CA: a cancer journal for clinicians"},{"issue":"1","key":"ref2","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"RL Siegel","year":"2015","journal-title":"CA: a cancer journal for clinicians"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3816\/CCC.2005.n.043","article-title":"Cancer and Leukemia Group B\/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma","volume":"5","author":"AP Venook","year":"2005","journal-title":"Clin Colorectal Cancer"},{"issue":"20","key":"ref4","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.24527","article-title":"Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients","volume":"115","author":"H Sorbye","year":"2009","journal-title":"Cancer"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"V Heinemann","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"13","key":"ref6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"C Cremolini","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"9209","key":"ref7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"JY Douillard","year":"2000","journal-title":"The Lancet"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"A de Gramont","year":"2000","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2 Suppl","key":"ref9","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"E Raymond","year":"1998","journal-title":"Seminars in oncology"},{"issue":"3","key":"ref10","first-page":"227","article-title":"Cellular and molecular pharmacology of oxaliplatin","volume":"1","author":"E Raymond","year":"2002","journal-title":"Molecular cancer therapeutics"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"C Tournigand","year":"2004","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1006\/bbrc.1997.7059","article-title":"Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress","volume":"236","author":"S Danno","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt 9","key":"ref13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1242\/jcs.01026","article-title":"Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism","volume":"117","author":"S Wellmann","year":"2004","journal-title":"J Cell Sci"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbcan.2009.11.001","article-title":"A new generation of proto-oncogenes: Cold-inducible RNA binding proteins","volume":"1805","author":"ME Lleonart","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1203\/PDR.0b013e3181c13326","article-title":"The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death","volume":"67","author":"S Wellmann","year":"2010","journal-title":"Pediatric research"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1479-5876-8-78","article-title":"Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer","volume":"8","author":"A Ehlen","year":"2010","journal-title":"J Transl Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1479-5876-9-114","article-title":"Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmo Diet and Cancer Study","volume":"9","author":"L Jonsson","year":"2011","journal-title":"J Transl Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2490-13-17","article-title":"Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer","volume":"13","author":"K Boman","year":"2013","journal-title":"BMC Urol"},{"issue":"11\u201312","key":"ref19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/prca.201100020","article-title":"High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer","volume":"5","author":"B Hjelm","year":"2011","journal-title":"Proteomics Clin Appl"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/modpathol.2009.124","article-title":"Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer","volume":"22","author":"A Jogi","year":"2009","journal-title":"Mod Pathol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"e0121300","DOI":"10.1371\/journal.pone.0121300","article-title":"Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer","volume":"10","author":"SE Olofsson","year":"2015","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2050-7771-2-11","article-title":"High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death","volume":"2","author":"L Jonsson","year":"2014","journal-title":"Biomark Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/his.12726","article-title":"RBM3 expression loss is associated with right-sided localization and poor prognosis in colorectal cancer","volume":"68","author":"N Melling","year":"2015","journal-title":"Histopathology"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.21873\/anticanres.11511","article-title":"Expression of RNA-binding Motif Protein 3 (RBM3) and Cold-inducible RNA-binding protein (CIRP) Is Associated with Improved Clinical Outcome in Patients with Colon Cancer","volume":"37","author":"HH Jang","year":"2017","journal-title":"Anticancer research"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"e0131046","DOI":"10.1371\/journal.pone.0131046","article-title":"High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS\/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort","volume":"10","author":"H Sorbye","year":"2015","journal-title":"PLoS One"},{"issue":"6220","key":"ref26","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"M Uhlen","year":"2015","journal-title":"Science (New York, NY)"},{"issue":"63","key":"ref27","doi-asserted-by":"crossref","DOI":"10.3791\/3620","article-title":"Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas","author":"C Kampf","year":"2012","journal-title":"J Vis Exp"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.2011.19","article-title":"BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer","volume":"104","author":"T Yokota","year":"2011","journal-title":"Br J Cancer"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1177\/000313480407001215","article-title":"Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status","volume":"70","author":"GL Piper","year":"2004","journal-title":"The American surgeon"},{"issue":"3b","key":"ref30","first-page":"1797","article-title":"Changes in tumour biological markers during primary systemic chemotherapy (PST)","volume":"28","author":"H Neubauer","year":"2008","journal-title":"Anticancer research"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/S0002-9440(10)63075-1","article-title":"Tissue microarrays for rapid linking of molecular changes to clinical endpoints","volume":"159","author":"J Torhorst","year":"2001","journal-title":"The American journal of pathology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:33:13Z","timestamp":1692923593000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182512"}},"subtitle":[],"editor":[{"given":"Rafael","family":"Rosell","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182512","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}